How should site staff run the informed consent process?

Informed consent is a process, not a signature: the participant receives clear information, has ample time and the chance to ask questions, decides freely, and only then signs and dates a consent form the IRB or ethics committee has given a favorable opinion to (ICH E6(R3) 2.8.6).

The investigator or delegated site staff run the discussion (ICH E6(R3) 2.8.5), the participant receives a copy of the signed form (ICH E6(R3) 2.8.11), and new information that may change their willingness to continue is shared and documented (ICH E6(R3) 2.8.2).

Before the conversation

  • Use only the current consent materials with the IRB's documented favorable opinion (ICH E6(R3) 2.8.1(a)).
  • Make sure the person obtaining consent is delegated to do it (ICH E6(R3) 2.8.5).
  • Confirm the person's identity, in person or remotely (ICH E6(R3) 2.8.1(e)).

During the conversation

  • Explain the purpose, procedures, foreseeable risks and benefits, alternatives, compensation for injury, expenses, and that participation is voluntary, among the other items the guideline lists (ICH E6(R3) 2.8.10).
  • Use clear, simple language; text, images, video and remote discussion are all allowed (ICH E6(R3) 2.8.1(b)).
  • Give ample time and answer every question to the person's satisfaction (ICH E6(R3) 2.8.6).
  • Never coerce or unduly influence anyone to take part or to stay (ICH E6(R3) 2.8.3).
  • If the person cannot read, an impartial witness is present for the entire discussion and signs too (ICH E6(R3) 2.8.9).

After the conversation

  • The participant, and the person who conducted the discussion, sign and date the form before any trial procedure (ICH E6(R3) 2.8.7).
  • The participant receives a copy of the signed form (ICH E6(R3) 2.8.11). US regulations also require the copy (21 CFR 50.27(a)).
  • Document the process in the source record: who explained what, when, the questions asked, and that consent came before any study procedure (21 CFR 312.62(b)).

US elements of consent

For FDA-regulated research, the consent must include the basic elements in 21 CFR 50.25(a): that the study involves research and its purpose and procedures, foreseeable risks, expected benefits, alternatives, confidentiality, compensation and treatment for injury when risk is more than minimal, whom to contact, and that participation is voluntary and can stop at any time without penalty (21 CFR 50.25(a)).

Questions people also ask

Can a coordinator obtain consent?

Yes, if the investigator has delegated the task and the coordinator is qualified and trained for it (ICH E6(R3) 2.8.5).

When is re-consent needed?

When new information could affect a participant's willingness to continue, it is assessed to decide whether re-consent is needed; revised materials need the IRB's favorable opinion before use (ICH E6(R3) 2.8.2).

Can consent be obtained remotely or electronically?

Yes, where appropriate; the investigator must still confirm the person's identity, and participants may be offered paper as an alternative (ICH E6(R3) 2.8.1(c)).

What about minors?

A legally acceptable representative consents, and the minor receives age-appropriate information and gives assent as appropriate (ICH E6(R3) 2.8.12).

Primary sources

  • ICH E6(R3) Guideline for Good Clinical Practice, final version adopted 6 January 2025 (ICH): https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf
  • 21 CFR 50.25: Elements of informed consent (eCFR): https://www.ecfr.gov/current/title-21/section-50.25
  • 21 CFR 50.27: Documentation of informed consent (eCFR): https://www.ecfr.gov/current/title-21/section-50.27

Last reviewed

2026-11-12